Vector Development

Gene Expression Levels Vary With Transgene Promoter Usage

Published in Gene Therapy Weekly, June 28th, 2001

by Deborah W. Heinrich, PhD, staff medical writer - In a recently reported study, retrovirally-mediated glucose 6-phosphate dehydrogenase (hG6PD) transgene expression levels were more consistent when hG6PD was driven by its own promoter.

According to M. De Angioletti and colleagues, Memorial Sloan-Kettering Cancer Center, retrovirus vectors are beneficial in the treatment of heritable genetic disorders because they possess the capability for permanent transgene expression after integration into the host genome. Unfortunately, they warned, levels of transgene expression after insertion can vary widely as retroviral promoters are influenced by promoters and regulatory...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-06-28)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry